PRA adds large molecule capabilities to its U.S. lab
CRO PRA intends to add immunochemistry services in its Lenexa, Kan., laboratory. PRA now has full-service bioanalytical capabilities near its clinics to support rapid results from phase I clinical studies in both the U.S. and Europe, facilitating complex and adaptive study design.
"By expanding our services to large molecule bioanalysis, we now can support all types of clinical trials," said Chad Briscoe, Ph.D, PRA executive director, science and innovations, bioanalytical laboratories. "It is an important addition to our services because the contribution of large molecules in drug research and the development of biosimilars have increased rapidly over the past few years."